Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia

被引:12
|
作者
Olsen, Mikkel Thor [1 ]
Dungu, Arnold Matovu [2 ]
Klarskov, Carina Kirstine [1 ]
Jensen, Andreas Kryger [4 ,5 ]
Lindegaard, Birgitte [2 ,3 ]
Kristensen, Peter Lommer [1 ,3 ]
机构
[1] Copenhagen Univ Hosp North Zealand, Dept Endocrinol & Nephrol, Hillerod, Denmark
[2] Copenhagen Univ Hosp North Zealand, Dept Pulm & Infect Dis, Hillerod, Denmark
[3] Copenhagen Univ Hosp North Zealand, Fac Hlth & Med Sci, Dept Clin Med, Hillerod, Denmark
[4] Univ Copenhagen, Dept Publ Hlth, Biostat, Oster Farimagsgade 5, DK-1014 Copenhagen, Denmark
[5] Copenhagen Univ Hosp North Zealand, Dept Clin Res, Hillerod, Denmark
关键词
Chronic obstructive pulmonary disease; Community-acquired pneumonia; Continuous glucose monitoring; Diabetes mellitus; Glucocorticoid-induced hyperglycemia; Glycemic variability; Length of stay; LENGTH-OF-STAY; MORTALITY; OUTCOMES; HYPERGLYCEMIA; IMPACT;
D O I
10.1186/s12890-022-01874-7
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Glycemic variability (GV) has only been sparsely studied in patients with community-acquired pneumonia (CAP). This study aimed to quantify in-hospital GV in CAP patients, including determining the impact of type 2 diabetes mellitus (T2DM) and glucocorticoid (GC) treatment on GV. Methods This is a prospective cohort study of CAP patients (N = 40) with or without T2DM and treated or not with GCs. The primary endpoint was GV measured as glucose standard deviation (SD), coefficient of variation (CV), and postprandial glucose excursions (PPGE) based on continuous glucose monitoring (CGM). Analysis of glucose data was split into daytime and nighttime when possible. Results Patients included had a mean age of 74 (range 55 to 91) years. SD (95%CI) increased by a factor of 1.93 (1.40 to 2.66) and 2.29 (1.38 to 3.81) in patients with T2DM and not treated with GCs during the daytime and the nighttime, respectively (both P < 0.01), and by a factor of 1.42 (1.04 to 1.97) in patients treated with GCs but without T2DM during the daytime (P = 0.031) compared to patients without T2DM and not treated with GCs. CV (95%CI) increased by 5.1 (0.0 to 10.1) and 8.1 (1.0 to 15.2) percentage points during the daytime and the nighttime, respectively, in patients with T2DM and not treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.046 and P = 0.026, respectively). PPGE (95% CI) increased during lunch by 2.5 (0.7 to 4.3) mmol/L (45 (13 to 77) mg/dL) in patients with T2DM and treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.018). Conclusions CAP patients receiving GCs, especially those with T2DM, are at great risk of developing high GV and therefore require clinical attention to mitigate GV. This applies particularly during the daytime. Results support the 1 to 2-h post-lunch screening procedure for glucocorticoid-induced hyperglycemia in patients without diabetes. SD was positively correlated with hospital length of stay.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
    Mikkel Thor Olsen
    Arnold Matovu Dungu
    Carina Kirstine Klarskov
    Andreas Kryger Jensen
    Birgitte Lindegaard
    Peter Lommer Kristensen
    [J]. BMC Pulmonary Medicine, 22
  • [2] Treatment of hospitalized patients with community-acquired pneumonia
    Leenders, ACAP
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 109 - 110
  • [3] PROGNOSIS OF PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
    FINE, MJ
    ORLOFF, JJ
    ARISUMI, D
    FANG, G
    ARENA, VC
    HANUSA, BH
    YU, VL
    SINGER, DE
    KAPOOR, WN
    [J]. AMERICAN JOURNAL OF MEDICINE, 1990, 88 (5N): : N1 - N8
  • [4] Prognosis of hospitalized patients with community-acquired pneumonia
    Akyil, F. Tokgoz
    Yalcinsoy, M.
    Hazar, A.
    Cilli, A.
    Celenk, B.
    Kilic, O.
    Sayiner, A.
    Kokturk, N.
    Coskun, A. Sakar
    Filiz, A.
    Edis, E. Cakir
    [J]. PULMONOLOGY, 2018, 24 (03): : 164 - 169
  • [5] Eosinopenia in Hospitalized Patients With Community-acquired Pneumonia
    Farah, W. H.
    Odeyemi, Y.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] Corticosteroids for Hospitalized Patients with Community-Acquired Pneumonia
    Cayley, William E., Jr.
    [J]. AMERICAN FAMILY PHYSICIAN, 2020, 102 (05) : 272 - 273
  • [7] Epidemiology of Community-Acquired Pneumonia in Hospitalized Pediatric Patients
    Regueras Santos, L.
    Iglesias Blazquez, C.
    Ledesma Benitez, I.
    Roson Varas, M.
    Lapena Lopez De Armentia, S.
    Gutierrez Garcia, P.
    [J]. BOLETIN DE PEDIATRIA, 2008, 48 (203): : 37 - 45
  • [8] Utilization of CT in patients hospitalized with community-acquired pneumonia
    Hofmann, LV
    Beall, DP
    Scott, WW
    Kuhlman, JE
    Moore, RD
    Mundy, LM
    [J]. RADIOLOGY, 1996, 201 : 549 - 549
  • [9] Prediction of Mortality in Community-Acquired Pneumonia in Hospitalized Patients
    Musonda, Patrick
    Sankaran, Prasanna
    Subramanian, Deepak N.
    Smith, Alexandra C.
    Prentice, Philippa
    Tariq, Syed M.
    Kamath, Ajay V.
    Myint, Phyo K.
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 342 (06): : 489 - 493
  • [10] True incidence of community-acquired pneumonia in hospitalized patients
    Ngan, Sharon
    Kumaran, Rani
    Prasad, Ashok
    Saleh, Anthony
    George, Liziamma
    Raoof, Suhail
    [J]. CHEST, 2006, 130 (04) : 127S - 127S